Shihyoung Kim

Mr. Shihyoung Kim

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SKShihyoung Kim
Shihyoung Kim
RSRAJNI KANT SHUKLA
RAJNI KANT SHUKLA
EKEunsoo Kim
Eunsoo Kim
SCSophie G. Cressman
Sophie G. Cressman
HYHannh Yu
Hannh Yu
SKSanggu Kim
Sanggu Kim
Anti-CD3-epsilon (CD3e) monoclonal antibodies (mAbs) and CD3e immunotoxins (ITs) are promising targeted therapy options for various T-cell disorders. Despite significant advances in mAb and IT engineering, vascular leakage syndrome (VLS) remains a major dose-limiting toxicity for ITs and has been poorly characterized for recent “engineered” mAbs. This study undertakes a direct comparison of non-mitogenic CD3e-mAb (145-2C11 with Fc-silentTM murine IgG1: S-CD3e-mAb) and a new murine-version CD3e-IT (saporin–streptavidin (sZAP) conjugated with S-CD3e-mAb: S-CD3e-IT) and identifies their distinct toxicity profiles in mice. As expected, the two agents showed different modes of action on T cells, with S-CD3e-mAb inducing nearly complete modulation of CD3e on the cell surface, while S-CD3e-IT depleted the cells. S-CD3e-IT significantly increased the infiltration of polymorphonuclear leukocytes (PMNs) into the tissue parenchyma of the spleen and lungs, a sign of increased vascular permeability. By contrast, S-CD3e-mAbs-treated mice showed no notable signs of vascular leakage. Treatment with control ITs (sZAP conjugated with Fc-silent isotype antibodies) induced significant vascular leakage without causing T-cell deaths. These results demonstrate that the toxin portion of S-CD3e-IT, not the CD3e-binding portion (S-CD3e-mAb), is the main driver of vascular leakage, thus clarifying the molecular target for improving safety profiles in CD3e-IT therapy.

28 August 2023 in Heliyon
Verified
Journal Article
Open access
LWLan Wang
Lan Wang
GSGajendra W. Suryawanshi
Gajendra W. Suryawanshi
SKShihyoung Kim
Shihyoung Kim
XGXin Guan
Xin Guan
ABAylin C. Bonifacino
Aylin C. Bonifacino
ICIrvin S.Y. Chen
Irvin S.Y. Chen
Selective T-cell depletion prior to cell or organ transplantation is considered a preconditioning regimen to induce tolerance and immunosuppression. An immunotoxin consisting of a recombinant anti-CD3 antibody conjugated with diphtheria toxin was used to eliminate T-cells. It showed significant T-cell depletion activity in the peripheral blood and lymph nodes in animal models used in previous studies. To date, a comprehensive evaluation of T-cell depletion and CD3 proliferation for all lymphoid tissues has not been conducted. Here, two rhesus macaques were administered A-dmDT390-SCFBdb (CD3-IT) intravenously at 25 μg/kg twice daily for four days. Samples were collected one day prior to and four days post administration. Flow cytometry and immunofluorescence staining were used to evaluate treatment efficiency accurately. Our preliminary results suggest that CD3-IT treatment may induce higher depletion of CD3 and CD4 T-cells in the lymph nodes and spleen, but is ineffective in the colon and thymus. The data showed a better elimination tendency of CD4 T-cells in the B-cell zone relative to the germinal center in the lymph nodes. Further, CD3-IT treatment may lead to a reduction in germinal center T follicular helper CD4 cells in the lymph nodes compared to healthy controls. The number of proliferating CD3 T-cell indicated that repopulation in different lymphoid tissues may occur four days post treatment. Our results provide insights into the differential efficacy of CD3-IT treatment and T-cell proliferation post treatment in different lymphoid tissues. Overall, CD3-IT treatment shows potential efficacy in depleting T-cells in the periphery, lymph nodes, and spleen, making it a viable preconditioning regimen for cell or organ transplantation. Our pilot study provides critical descriptive statistics and can contribute to the design of larger future studies.

25 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SKShihyoung Kim
Shihyoung Kim
RSRajni Kant Shukla
Rajni Kant Shukla
HYHannah Yu
Hannah Yu
ABAlice Baek
Alice Baek
SCSophie G Cressman
Sophie G Cressman
SKSanggu Kim
Sanggu Kim
CD3-epsilon(CD3e) immunotoxins (IT), a promising precision reagent for various clinical conditions requiring effective depletion of T cells, often shows limited treatment efficacy for largely unknown reasons. Tissue-resident T cells that persist in peripheral tissues have been shown to play pivotal roles in local and systemic immunity, as well as transplant rejection, autoimmunity and cancers. The impact of CD3e-IT treatment on these local cells, however, remains poorly understood. Here, using a new murine testing model, we demonstrate a substantial enrichment of tissue-resident Foxp3+ Tregs following CD3e-IT treatment. Differential surface expression of CD3e among T-cell subsets appears to be a main driver of Treg enrichment in CD3e-IT treatment. The surviving Tregs in CD3e-IT-treated mice were mostly the CD3e dim CD62L lo effector phenotype, but the levels of this phenotype markedly varied among different lymphoid and nonlymphoid organs. We also found notable variations in surface CD3e levels among tissue-resident T cells of different organs, and these variations drive CD3e-IT to uniquely reshape T-cell compositions in local organs. The functions of organs and anatomic locations (lymph nodes) also affected the efficacy of CD3e-IT. The multi-organ pharmacodynamics of CD3e-IT and potential treatment resistance mechanisms identified in this study may generate new opportunities to further improve this promising treatment.

6 November 2026 in Research Square
Verified
Preprint
Open access
PDF file
SKShihyoung Kim
Shihyoung Kim
RSRajni Kant Shukla
Rajni Kant Shukla
SGSarah Golconda
Sarah Golconda
HYHannah Yu
Hannah Yu
JRJohn C. Reneau
John C. Reneau
SKSanggu Kim
Sanggu Kim
Targeted lymphodepletion with CD3 immunotoxins (CD3-ITs) is promising for transplantation and T-cell malignancies, but incomplete tissue depletion limits efficacy. We used a murine anti-CD3 immunotoxin model, intravascular staining, histology, and CD4-iDTR mice to define factors associated with survival of follicular T cells. CD3-IT caused profound systemic T-cell depletion and enrichment of follicular helper (T FH ) and follicular regulatory (T FR ) T cells among surviving CD4 + cells in spleen, Peyer’s patches, and lymph nodes. Ex vivo, CXCR5 + T cells bound CD3-IT comparably to CXCR5 - cells and showed similar susceptibility to CD3-IT-mediated cytotoxicity (IC 50 , 0.471–0.569 nM). In contrast, within the splenic parenchyma, CXCR5 + T cells bound CD3-IT at approximately half the level of CXCR5 − counterparts ( p < 0.05). Histologically, CD3-IT depleted 83% of T cells in splenic T-cell zones, whereas GC T cells were relatively spared. Fc-silent anti-CD40L pretreatment disrupted GC architecture and was associated with a marked reduction in the phenotypic T FH compartment after CD3-IT treatment. In CD4-iDTR mice, free diphtheria toxin (DT) and CD3-IT produced substantially less depletion of GC than T-cell-zone T cells, whereas Fc-silent anti-CD3 mAb down-modulated CD3 on GC-T FH cells. BrdU incorporation did not indicate disproportionate GC-T FH proliferation, and relative sparing with both a 58-kDa free DT and a 278-kDa CD3-IT indicates that size alone is insufficient to explain the effect in intact germinal centers in vivo . Together, these data show that intact GC architecture creates a functional barrier to toxin-mediated depletion of resident follicular T cells.